Status:

COMPLETED

the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

Lead Sponsor:

Fayoum University

Collaborating Sponsors:

Ministry of Health and Population, Egypt

Conditions:

SARS-CoV2 Infection

Eligibility:

All Genders

18-60 years

Brief Summary

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiote...

Detailed Description

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands a...

Eligibility Criteria

Inclusion

  • A diagnosis of SARS-CoV2 with PCR.
  • Age range from 18-60 years old
  • Hospital admission not more than 10 days

Exclusion

  • Pregnancy or contraceptive pills
  • Lactation
  • Any auto-immune disease that could affect the oral mucosa
  • On any neoplastic therapy.
  • Uncontrolled diabetes.

Key Trial Info

Start Date :

May 20 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 15 2021

Estimated Enrollment :

385 Patients enrolled

Trial Details

Trial ID

NCT04893694

Start Date

May 20 2021

End Date

July 15 2021

Last Update

August 24 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Dentistry

Al Fayyum, Egypt, 63514

the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection | DecenTrialz